Gutniak M, Orskov C, Holst JJ, et al
Providers should concentrate on three areas: With these programs and mostly limited adaptations of existing solutions, there is significant market potential for digital weight loss and behavior change-supporting solutions
SELECT Showed 10% GI Discontinuation Over Nearly Four Years The SELECT trial followed 17,604 adults on semaglutide for a median of 39.8 months
Doi: 19
Because retatrutide has not yet received MHRA or EMA approval, it is not currently available through NHS prescriptions or licensed private clinics in the UK
The design works because the GLP-1 and GIP arms buffer that glucose-raising tendency, leaving glucagon free to do something useful: push up energy expenditure, encourage the liver to burn its own fat stores, and increase the rate at which the body turns over lipids